Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Trade-Ideas LLC identified

iBio

(

IBIO

) as a strong on high relative volume candidate. In addition to specific proprietary factors, Trade-Ideas identified iBio as such a stock due to the following factors:

  • IBIO has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $22.7 million.
  • IBIO has traded 7.4 million shares today.
  • IBIO is trading at 104.32 times the normal volume for the stock at this time of day.
  • IBIO is trading at a new high 56.04% above yesterday's close.

'Strong on High Relative Volume' stocks are worth watching because major volume moves tend to indicate underlying activity such as M&A events, material stock news, analyst upgrades, insider buying, buying from 'superinvestors,' or that hedge funds and momentum traders are piling into a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize. In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in IBIO with the Ticky from Trade-Ideas. See the FREE profile for IBIO NOW at Trade-Ideas

More details on IBIO:

iBio, Inc., a biotechnology company, focuses on the commercialization of its proprietary plant-based protein expression technologies in the United States and internationally.

The average volume for iBio has been 357,400 shares per day over the past 30 days. iBio has a market cap of $36.8 million and is part of the health care sector and drugs industry. The stock has a beta of 0.90 and a short float of 0.2% with 0.01 days to cover.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null